Integrated bioinformatics analysis of chromatin regulator EZH2 in regulating mRNA and lncRNA expression by ChIP sequencing and RNA sequencing
Metrics: PDF 1839 views | HTML 2675 views | ?
Yuan Li1, Mei Luo2, Xuejiao Shi1, Zhiliang Lu1, Shouguo Sun1, Jianbing Huang1, Zhaoli Chen1, Jie He1
1Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, People’s Republic of China
2Central Laboratory, Beijing Luhe Hospital, Capital Medical University, Beijing, People’s Republic of China
Zhaoli Chen, email: [email protected]
Jie He, email: [email protected]
Keywords: EZH2, ChIP sequencing, RNA-sequencing, long noncoding RNA, cancer
Received: August 23, 2016 Accepted: October 24, 2016 Published: November 07, 2016
Enhancer of zeste homolog 2 (EZH2), a dynamic chromatin regulator in cancer, represents a potential therapeutic target showing early signs of promise in clinical trials. EZH2 ChIP sequencing data in 19 cell lines and RNA sequencing data in ten cancer types were downloaded from GEO and TCGA, respectively. Integrated ChIP sequencing analysis and co-expressing analysis were conducted and both mRNA and long noncoding RNA (lncRNA) targets were detected. We detected a median of 4,672 mRNA targets and 4,024 lncRNA targets regulated by EZH2 in 19 cell lines. 20 mRNA targets and 27 lncRNA targets were found in all 19 cell lines. These mRNA targets were enriched in pathways in cancer, Hippo, Wnt, MAPK and PI3K-Akt pathways. Co-expression analysis confirmed numerous targets, mRNA genes (RRAS, TGFBR2, NUF2 and PRC1) and lncRNA genes (lncRNA LINC00261, DIO3OS, RP11-307C12.11 and RP11-98D18.9) were potential targets and were significantly correlated with EZH2. We predicted genome-wide potential targets and the role of EZH2 in regulating as a transcriptional suppressor or activator which could pave the way for mechanism studies and the targeted therapy of EZH2 in cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.